Cited by 106Lipid metabolism and disordersLiver Disease Diagnosis and TreatmentLipoproteins and Cardiovascular Health

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

Hepatic and Cardiovascular Consequences of Familial Hypobetalipoproteinemia

Sankatsing, Raaj R., Fouchier, Sigrid W., de Haan, Stefan, Hutten, Barbara A., de Groot, Eric, Kastelein, John J.P., Stroes, Erik S.G.·2005·Arteriosclerosis, Thrombosis, and Vascular Biology

DOI 10.1161/01.atv.0000176191.64314.07

Open this paper in CoChat — free account

Abstract

Objective— Individuals with familial hypobetalipoproteinemia (FHBL) have been reported to be prone to fatty liver disease (FLD). Conversely, the profound reduction of low-density lipoprotein (LDL) cholesterol in this disorder might decrease cardiovascular risk. In the present study, we assessed hepatic steatosis as well as noninvasive surrogate markers for cardiovascular disease (CVD) in subjects with FHBL and in matched controls. Methods and Results— Hepatic steatosis was assessed by abdominal ultrasonography. Carotid intima-media thickness (IMT) and distal common carotid arterial wall stiffness as surrogate markers for CVD risk were measured using high-resolution B-mode ultrasonography. Whereas transaminase levels were only modestly elevated, both prevalence (54% versus 29%; P =0.01) and severity of steatosis were significantly higher in FHBL individuals compared with controls. Despite similar IMT measurements, arterial stiffness was significantly lower in FHBL ( P =0.04) compared with controls. Additionally, the increase in arterial stiffness as seen in the presence of traditional risk factors was attenuated, suggesting that very low levels of apoB-containing lipoproteins can negate the adverse effects of other risk factors on the vasculature. Conclusions— FHBL is characterized by an increased prevalence and severity of fatty liver disease. The observed decreased level of arterial wall stiffness, most pronounced in the presence of nonlipid risk factors, is indicative of cardiovascular protection in these subjects.

Integrity signals

Registry

Crossref · 10.1161/01.atv.0000176191.64314.07

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients
Laurent, S., Boutouyrie, P., Asmar, R., Gautier, I., Laloux, B., Guize, L., Ducimetiere, P., & Benetos, A. (2001) · Hypertension · doi:10.1161/01.hyp.37.5.1236 · Cited by 3,856
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,790
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Brown, B. G., Ganz, P., Vogel, R. A., Crowe, T., Howard, G., Cooper, C. J., Brodie, B. R., et al. (2004) · JAMA · doi:10.1001/jama.291.9.1071 · Cited by 2,361
Impact of Aortic Stiffness on Survival in End-Stage Renal Disease
Blacher, J., Guerin, A. P., Pannier, B., Marchais, S. J., Safar, M. E., & London, G. M. (1999) · Circulation · doi:10.1161/01.cir.99.18.2434 · Cited by 2,138
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Aortic Stiffness Is an Independent Predictor of Primary Coronary Events in Hypertensive Patients
Boutouyrie, P., Tropeano, A., Asmar, R. G., Gautier, I., Bénétos, A., Lacolley, P. J., & Laurent, S. (2002) · Hypertension · doi:10.1161/hy0102.099031 · Cited by 1,745
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Angulo, P., Keach, J. C., Batts, K. P., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510300604 · Cited by 1,609

Show all 56 references

Research works printed but not linked: 13

10.1161/atvb.18.11.1745 · DOI
10.1161/atvb.17.6.1032 · DOI
2002, Rev Gastroenterol Disord, 2, 11
2002, Semin Gastrointest Dis, 13, 17
10.1161/circ.91.5.1432 · DOI
10.1161/hyp.39.1.10 · DOI
10.1161/circ.105.3.310 · DOI
10.1161/circ.95.1.31 · DOI
2004, J Am Coll Cardiol, 43, A515.
10.1161/hyp.37.5.1236 · DOI
10.1161/circ.99.18.2434 · DOI
10.1161/atvb.21.12.2046 · DOI
10.1161/circ.68.1.6851054 · DOI

Sorted by citations

The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Non-alcoholic fatty liver disease and increased risk of cardiovascular disease
Targher, G., & Arcaro, G. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.021 · Cited by 551
Lomitapide and Mipomersen
Rader, D. J., & Kastelein, J. J. P. (2014) · Circulation · doi:10.1161/circulationaha.113.001292 · Cited by 265
Self-citation
Non-alcoholic fatty liver disease and risk of cardiovascular disease
Lonardo, A., Sookoian, S. C., Pirola, C. J., & Targher, G. (2015) · Metabolism · doi:10.1016/j.metabol.2015.09.017 · Cited by 236
Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy
McGowan, M. P., Tardif, J., Češka, R., Burgess, L. J., Soran, H., Gouni‐Berthold, I., Wagener, G., & Chasan-Taber, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049006 · Cited by 228
Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212
New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?
Sahebkar, A., & Watts, G. F. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6479-4 · Cited by 176
Molecular diagnosis of hypobetalipoproteinemia: An ENID review
Tarugi, P., Averna, M. R., Leo, E. D., Cefalu, A. B., Noto, D., Magnolo, L., Cattin, L., Bertolini, S., & Calandra, S. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.05.003 · Cited by 179
Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia
Filippo, M. D., Moulin, P., Roy, P., Bouma, M. E., Collardeau‐Frachon, S., Chebel-Dumont, S., Peretti, N., Dumortier, J., Zoulim, F., Fontanges, T., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.05.023 · Cited by 147
Genetic determinants of hepatic steatosis in man
Hooper, A. J., Adams, L. A., & Burnett, J. R. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r008896 · Cited by 149
Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology
Loria, P., Marchesini, G., Nascimbeni, F., Ballestri, S., Maurantonio, M., Carubbi, F., Ratziu, V., & Lonardo, A. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.10.030 · Cited by 136
Update on the molecular biology of dyslipidemias
Ramasamy, I. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.10.033 · Cited by 131
Hypobetalipoproteinemia
Tarugi, P., & Averna, M. R. (2011) · Advances in clinical chemistry · doi:10.1016/b978-0-12-387025-4.00004-2 · Cited by 127
Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers
Crooke, S. T., Baker, B. F., Kwoh, T. J., Cheng, W., Schulz, D. J., Xia, S., Salgado, N. R., Bui, H., Hart, C. E., Burel, S. A., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.136 · Cited by 118
Pharmacological strategies for lowering LDL cholesterol: statins and beyond
Brautbar, A., & Ballantyne, C. M. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.2 · Cited by 115
Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia
Visser, M. E., Akdim, F., Tribble, D. L., Nederveen, A. J., Kwoh, T. J., Kastelein, J. J. P., Trip, M. D., & Stroes, E. S. G. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m002915 · Cited by 112
Self-citation
Diagnosis and management of secondary causes of steatohepatitis
Liebe, R., Esposito, I., Bock, H. H., Dahl, S. V., Stindt, J., Baumann, U., Luedde, T., & Keitel, V. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.045 · Cited by 114
Antisense oligonucleotides for the treatment of dyslipidaemia
Visser, M. E., Witztum, J. L., Stroes, E. S. G., & Kastelein, J. J. P. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs084 · Cited by 102
Self-citation
Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism
Hooper, A. J., van Bockxmeer, F. M., & Burnett, J. R. (2005) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360500295113 · Cited by 89
Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis
Minicocci, I., Santini, S., Cantisani, V., Stitziel, N., Kathiresan, S., Arroyo, J. A., Martí, G., Pisciotta, L., Noto, D., Cefalù, A. B., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.p039875 · Cited by 97
A Locked Nucleic Acid Oligonucleotide Targeting MicroRNA 122 Is Well-Tolerated in Cynomolgus Monkeys
Hildebrandt-Eriksen, E. S., Aarup, V., Persson, R., Hansen, H. F., Munk, M. E., & Ørum, H. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2011.0332 · Cited by 97
Evidence-based goals in LDL-C reduction
Soran, H., Dent, R., & Durrington, P. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1069-7 · Cited by 92
Contemporary Aspects of the Biology and Therapeutic Regulation of the Microsomal Triglyceride Transfer Protein
Hooper, A. J., Burnett, J. R., & Watts, G. F. (2014) · Circulation Research · doi:10.1161/circresaha.116.304637 · Cited by 89
Lipoprotein metabolism in nonalcoholic fatty liver disease
Jiang, Z. G., Simon, K. A., & Zemin, Y. (2013) · Journal of Biomedical Research · doi:10.7555/jbr.27.20120077 · Cited by 89
Prevalence of ANGPTL3 and APOB Gene Mutations in Subjects With Combined Hypolipidemia
Noto, D., Cefalù, A. B., Valenti, V., Fayer, F., Pinotti, E., Ditta, M., Spina, R., Vigna, G., Yue, P., Kathiresan, S., et al. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.238766 · Cited by 81
A Novel APOB Mutation Identified by Exome Sequencing Cosegregates With Steatosis, Liver Cancer, and Hypocholesterolemia
Cefalu, A. B., Pirruccello, J. P., Noto, D., Gabriel, S., Valenti, V., Gupta, N., Spina, R., Tarugi, P., Kathiresan, S., & Averna, M. R. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.301101 · Cited by 86
Rare Protein-Truncating Variants in APOB , Lower Low-Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease
Peloso, G. M., Nomura, A., Khera, A. V., Chaffin, M. D., Won, H., Ardissino, D., Danesh, J., Schunkert, H., Wilson, J. G., Samani, N. J., et al. (2019) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002376 · Cited by 75
Missense Mutations in APOB within the βα1 Domain of Human APOB-100 Result in Impaired Secretion of ApoB and ApoB-containing Lipoproteins in Familial Hypobetalipoproteinemia
Burnett, J. R., Zhong, S., Jiang, Z. G., Hooper, A. J., Fisher, E. A., McLeod, R. S., Zhao, Y., Barrett, P. H. R., Hegele, R. A., BOCKXMEER, F. M. V., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702442200 · Cited by 71
How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol
Karagiannis, A. D., Mehta, A., Dhindsa, D. S., Virani, S. S., Orringer, C. E., Blumenthal, R. S., Stone, N. J., & Sperling, L. S. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1080 · Cited by 70
Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation
Martín-Campos, J. M., Roig, R., Mayoral, C., Martinez, S., Martí, G., Arroyo, J. A., Julve, J., & Blanco-Vaca, F. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.11.020 · Cited by 65
Noninvasive Differentiation between Hepatic Steatosis and Steatohepatitis with MR Imaging Enhanced with USPIOs in Patients with Nonalcoholic Fatty Liver Disease: A Proof-of-Concept Study
Smits, L. P., Coolen, B. F., Panno, M. D., Runge, J. H., Nijhof, W. H., Verheij, J., Nieuwdorp, M., Stoker, J., Beuers, U. H., Nederveen, A. J., et al. (2015) · Radiology · doi:10.1148/radiol.2015150952 · Cited by 60
Self-citation
Update on Primary Hypobetalipoproteinemia
Hooper, A. J., & Burnett, J. R. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0423-3 · Cited by 63
Anti-PCSK9 therapies for the treatment of hypercholesterolemia
Hooper, A. J., & Burnett, J. R. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.748743 · Cited by 46
Clinical and biochemical characteristics of individuals with low cholesterol syndromes: A comparison between familial hypobetalipoproteinemia and familial combined hypolipidemia
Costanzo, A. D., Leo, E. D., Noto, D., Cefalu, A. B., Minicocci, I., Polito, L., D’Erasmo, L., Cantisani, V., Spina, R., Tarugi, P., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.06.013 · Cited by 46
Familial Hypercholesterolemia: Present and Future Management
Sjouke, B., Kusters, D. M., Kastelein, J. J. P., & Hovingh, G. K. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0219-9 · Cited by 45
Self-citation
Apolipoprotein B synthesis inhibition: results from clinical trials
Visser, M. E., Kastelein, J. J. P., & Stroes, E. S. G. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833af4c1 · Cited by 41
Self-citation
ApoB100 and Atherosclerosis: What’s New in the 21st Century?
Kounatidis, D. C., Vallianou, N. G., Poulaki, A., Evangelopoulos, A. A., Panagopoulos, F., Stratigou, T., Geladari, E. V., Karampela, Ι., & Dalamaga, Μ. (2024) · Metabolites · doi:10.3390/metabo14020123 · Cited by 49
Safety and Effect of Very Low Levels of Low-Density Lipoprotein Cholesterol on Cardiovascular Events
LaRosa, J. C., Pedersen, T. R., Somaratne, R. M., & Wasserman, S. M. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.12.052 · Cited by 43
The influence of obesity and metabolic risk variables on brachial-ankle pulse wave velocity in healthy adolescents
Miyai, N., Arita, M., Miyashita, K., Morioka, I., & Takeda, S. (2008) · Journal of Human Hypertension · doi:10.1038/jhh.2008.143 · Cited by 41
Cryptogenic cirrhosis in a patient with familial hypocholesterolemia due to a new truncated form of apolipoprotein B
Bonnefont‐Rousselot, D., Condat, B., Sassolas, A., Chebel, S., Bittar, R., Federspiel, M.-C., Cazals-Hatem, D. L., & Bruckert, É. (2008) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3282ffd9f8 · Cited by 40
Genetics of Dyslipidemia
García-Giustiniani, D. A., & Stein, R. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160074 · Cited by 39
Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children
Page, M. M., Bell, D. A., Hooper, A. J., Watts, G. F., & Burnett, J. R. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.004 · Cited by 35
Gene-based therapy in lipid management: the winding road from promise to practice
Tromp, T. R., Stroes, E. S. G., & Hovingh, G. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1757070 · Cited by 33
Self-citation
Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population
Wargny, M., Goronflot, T., Rimbert, A., Boursier, J., Kab, S., Henny, J., Lainé, A., Leux, C., Smati, S., Hadjadj, S., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.030 · Cited by 28
Clinical Implications of Lipid Genetics for Cardiovascular Disease
Strong, A., & Rader, D. J. (2010) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-010-0131-7 · Cited by 29
Development of Apolipoprotein B Antisense Molecules as a Therapy for Hyperlipidemia
Thomas, T. A., & Ginsberg, H. N. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0078-7 · Cited by 27
Current and Future Pharmacologic Options for the Management of Patients Unable to Achieve Low-Density Lipoprotein-Cholesterol Goals with Statins
Harchaoui, K. E., Akdim, F., Stroes, E. S. G., Trip, M. D., & Kastelein, J. J. P. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200808040-00003 · Cited by 27
Self-citation
Sterol and lipid analyses identifies hypolipidemia and apolipoprotein disorders in autism associated with adaptive functioning deficits
Tierney, E., Remaley, A. T., Thurm, A., Jager, L. R., Wassif, C. A., Kratz, L. E., Bailey-Wilson, J. E., Bukelis, I., Sarphare, G., Jung, E. S., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01580-8 · Cited by 26
Efficacy and safety of PCSK9 monoclonal antibodies
Iqbal, Z., Dhage, S. S., Mohamad, J. B., Abdel-Razik, A. E. S., Donn, R. P., Malik, R. A., Ho, J. H., Liu, Y., Adam, S., Isa, B., et al. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1681395 · Cited by 26
New Clinical Perspectives of Hypolipidemic Drug Therapy in Severe Hypercholesterolemia
Stefanutti, C., Morozzi, C., & Giacomo, S. D. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803341485 · Cited by 23
Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterol–diabetes connection? A systematic review of literature
Noto, D., Arca, M., Tarugi, P., Cefalu, A. B., Barbagallo, C. M., & Averna, M. R. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0931-4 · Cited by 25
The strengths and limitations of the ApoB/ApoA-I ratio to predict the risk of vascular disease: a hegelian analysis
Sniderman, A. D., & Kiss, R. S. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0031-6 · Cited by 22
APOB-Related Familial Hypobetalipoproteinemia
Burnett, J. R., Hooper, A. J., & Hegele, R. A. (2021) · Europe PMC (PubMed Central) · Cited by 21
Extremely low levels of low-density lipoprotein potentially suggestive of familial hypobetalipoproteinemia: A separate phenotype of NAFLD?
Mouzaki, M., Shah, A. D., Arce‐Clachar, A. C., Hardy, J., Bramlage, K., & Xanthakos, S. A. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.02.002 · Cited by 22
Vitamin E and oxidative stress in abetalipoproteinemia and familial hypobetalipoproteinemia
Burnett, J. R., & Hooper, A. J. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.05.044 · Cited by 23
Homozygous familial hypobetalipoproteinemia: Two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature
Cefalu, A. B., Norata, G. D., Ghiglioni, D. G., Noto, D., Uboldi, P., Garlaschelli, K., Baragetti, A., Spina, R., Valenti, V., Pederiva, C., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.014 · Cited by 20
Is mipomersen ready for clinical implementation? A transatlantic dilemma
Sjouke, B., Balak, D., Beuers, U. H., Ratziu, V., & Stroes, E. S. G. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328362dfd9 · Cited by 20
Self-citation
Apolipoprotein B gene mutations and fatty liver in Japanese hypobetalipoproteinemia
Katsuda, S., Kawashiri, M., Inazu, A., Tada, H., Tsuchida, M., Kaneko, Y., Nozue, T., Nohara, A., Okada, T., Kobayashi, J., et al. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.09.021 · Cited by 20
Low cholesterol states: clinical implications and management
Gill, P. K., & Hegele, R. A. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204932 · Cited by 19
Low LDL cholesterol—Friend or foe?
Hartz, J. C., Hegele, R. A., & Wilson, D. P. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.006 · Cited by 17
Low LDL-C levels are associated with risk of mortality in a Chinese cohort study
Lu, J., Wu, M., Yang, Z., Zhu, Y., Li, D., Yu, Z., Shen, P., Tang, M., Jin, M., Lin, H., et al. (2021) · Endocrine · doi:10.1007/s12020-021-02746-6 · Cited by 17
Update on the diagnosis, treatment and management of rare genetic lipid disorders
Ng, D., Burnett, J. R., Bell, D. A., Hegele, R. A., & Hooper, A. J. (2018) · Pathology · doi:10.1016/j.pathol.2018.11.005 · Cited by 18
New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease
Burger, A. L., Pogran, E., Muthspiel, M., Kaufmann, C. C., Jäger, B., & Huber, K. (2022) · Biomedicines · doi:10.3390/biomedicines10050970 · Cited by 17
Genetics of Lipid Traits and Relationship to Coronary Artery Disease
Keenan, T. E., & Rader, D. J. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0396-9 · Cited by 16
Altered lipid metabolism and the development of metabolic-associated fatty liver disease
Foster, C., Gagnon, C. A., & Ashraf, A. P. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000933 · Cited by 19
Familial Defective Apolipoprotein B and Familial Hypobetalipoproteinemia in One Family: Two Neutralizing Mutations
van der Graaf, A., Fouchier, S. W., Vissers, M. N., Defesche, J. C., Wiegman, A., Sankatsing, R. R., Hutten, B. A., Trip, M. D., & Kastelein, J. J. P. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-9-200805060-00022 · Cited by 15
Self-citation
Managing recalcitrant hypercholesterolemia in patients on current best standard of care: efficacy and safety of novel pharmacotherapies
Sahebkar, A., & Watts, G. F. (2014) · Clinical Lipidology · doi:10.2217/clp.14.14 · Cited by 13
Angiopoietin-like 3 regulates hepatocyte proliferation and lipid metabolism in zebrafish
Lee, S.-H., So, J., Kim, H.-T., Choi, J., Lee, M., Choi, S., Kim, C., & Kim, J. M. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.03.099 · Cited by 13
Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia
Crooke, R. M., & Graham, M. J. (2011) · Clinical Lipidology · doi:10.2217/clp.11.59 · Cited by 11
Non-alcoholic steatohepatitis-related cirrhosis in a patient with APOB L343V familial hypobetalipoproteinaemia
Heeks, L. V., Hooper, A. J., Adams, L. A., Robbins, P. A., Barrett, P. H. R., BOCKXMEER, F. M. V., & Burnett, J. R. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.03.004 · Cited by 12
LDL-C-Lowering therapy: Current and future therapeutic targets
Visser, M. E., Jakulj, L., Kastelein, J. J. P., & Stroes, E. S. G. (2008) · Current Cardiology Reports · doi:10.1007/s11886-008-0080-7 · Cited by 12
Self-citation
Age-Specific Nomogram of Brachial-Ankle Pulse Wave Velocity in Japanese Adolescents
Miyai, N., Utsumi, M., Gowa, Y., Igarashi, Y., Miyashita, K., Takeda, S., & Arita, M. (2012) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2012.690473 · Cited by 11
Discordance between apolipoprotein B or non-HDL-cholesterol and LDL-cholesterol in middle-aged and elderly Chinese patients predicts arterial stiffness
Qu, G., Zhang, Z., & Zhu, H. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01509-6 · Cited by 11
Familial hypobetalipoproteinemia: Analysis of three Spanish cases with two new mutations in the APOB gene
Martín-Morales, R., García-Díaz, J. D. D., Tarugi, P., González‐Santos, P., Saavedra-Vallejo, P., Magnolo, L., Mesa-Latorre, J. M., Leo, E. D., & Valdivielso, P. (2013) · Gene · doi:10.1016/j.gene.2013.08.049 · Cited by 10
Does inhibition of apolipoprotein B synthesis produce foie gras?
Feingold, K. R. (2009) · Journal of Lipid Research · doi:10.1194/jlr.e005140 · Cited by 10
Antisense technology to lower LDL cholesterol
Neely, R. D. G., & Bassendine, M. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60364-9 · Cited by 10
Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia?
Ballestri, S., Lonardo, A., Losi, L., Pellegrini, E., Bertolotti, M., & Loria, P. (2008) · Internal and Emergency Medicine · doi:10.1007/s11739-008-0178-3 · Cited by 9
Prevalence of Liver Steatosis and Fibrosis in Adults With Primary Hypobetaliproteinemia: Results From the HYPOCHOL Study
Smati, S., Wargny, M., Boursier, J., Moulin, P., Filippo, M. D., & Cariou, B. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.06.031 · Cited by 8
Antisense oligonucleotides in the treatment of lipid disorders: pitfalls and promises.
Besseling, J., Hovingh, G. K., & Stroes, E. S. G. (2013) · PubMed · Cited by 8
Self-citation
Drug targets beyond HMG-CoA reductase: Why venture beyond the statins?
Gelissen, I. C., & Brown, A. J. (2011) · Frontiers in Biology · doi:10.1007/s11515-011-1130-x · Cited by 8
Targeting ApoB as a therapeutic approach for the treatment of dyslipidemia: the potential role of mipomersen
Thomas, T. A., & Ginsberg, H. N. (2010) · Clinical Lipidology · doi:10.2217/clp.10.47 · Cited by 7
Apolipoprotein‐B
Williams, K. J., & Fisher, E. A. A. (2015) · Atherosclerosis · doi:10.1002/9781118828533.ch24 · Cited by 5
Novel Prognostic Indicators to reflect the grade of liver fibrosis in hepatic patients
El-Gazar, M. M. A., Fahmi, A. E., mohamed, A., & Elhakim, H. A. (2021) · Egyptian Journal of Chemistry · doi:10.21608/ejchem.2021.104682.4837 · Cited by 4
Hipobetalipoproteinemia familiar secundaria a mutación en el gen de la apolipoproteína B
Blanco-Rodríguez, M., Muñoz-Calvo, M. A., Martos‐Moreno, G. Á., Abad, E., & Argente-Oliver, J. (2007) · Anales de Pediatría · doi:10.1157/13102518 · Cited by 3
Rare primary dyslipidaemias associated with low LDL and HDL cholesterol values in Portugal
Alves, A. C., Miranda, B., Moldovan, O., Santo, R. E., Silva, R. G., Cardoso, S. S., Diogo, L. M., Seidi, M., Sequeira, S., & Bourbon, M. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1088040 · Cited by 3
Genetics of familial hypobetalipoproteinemia
Tarugi, P., & Averna, M. R. (2007) · Future Lipidology · doi:10.2217/17460875.2.6.615 · Cited by 2
Health Outcomes Associated with Hypolipidemia: a Scoping Review
Hong, S., Choi, D.-J., & Jeong, J.-C. (2025) · The Journal of Internal Korean Medicine · doi:10.22246/jikm.2025.46.1.61 · Cited by 1
DYSLIPIDEMIAS
Murphy, M. S., & O’Brien, T. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50027-5 · Cited by 2
MOLECULAR CHARACTERIZATION AND SPECTRUM OF MUTATIONS ASSOCIATED WITH AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA
D’Agostino, M. N. (2014)
Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL
Schwarz, M., & Kim, J. B. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch8
Exome sequencing identifies novel ApoB loss-of-function mutations causing hypobetalipoproteinemia in type 1 diabetes
Gao, F., Luo, H., Fu, Z., Zhang, C., & Zhang, R. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0687-7
Conséquences métaboliques des malabsorptions lipidiques : apports de l’étude des hypocholestérolémies familiales
Peretti, N. (2012) · Oléagineux Corps gras Lipides · doi:10.1051/ocl.2012.0463
Novel Mutation in the Apob Gene (Apo B-15.56): A Case Report
Bove, M., Carnevali, L., Cicero, A. F. G., Tarugi, P., & Gaddi, A. V. (2010) · Balkan Journal of Medical Genetics · doi:10.2478/v10034-010-0029-1
Ailesel hipobetalipoproteinemiye bağli non-alkolik steatohepatitli hastalarda ursodeoksikolik asit tedavisi
Çıçek, B., Köksal, A. Ş., Oğuz, D., Erden, E., Parlak, E., & Şahın, B. (2005) · Akademik Gastroenteroloji Dergisi · doi:10.17941/agd.40942
Familial Low-Cholesterol Syndromes or Hypobetalipoproteinemias
Noto, D., Tarugi, P., & Averna, M. R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.98702-6
Formes rares de dyslipidémies génétiques
Luc, G. (2010) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(10)51264-2
Hepatosteatosis may reveal heterozygous familial hypobetalipoproteinemia
Mazokopakis, E. E., Karefilaki, S., Syros, P. K., & Lioudaki, E. (2013)
Current World Literature
(2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000244230.06529.0f
Primär genetische Dyslipoproteinämien und Atheroskleroserisiko
Schwab, K. O., & Doerfer, J. (2022) · Springer eBooks · doi:10.1007/978-3-662-63320-5_3
Primer hipolipoproteinemili hastalarda monosit/yüksek yoğunluklu lipoprotein kolesterol oranı
Tekin, M. Ş. (2022) · DergiPark (Istanbul University) · doi:10.47582/jompac.1162205

Authors: Sankatsing, R. R., Fouchier, S. W., de Haan, S., Hutten, B. A., de Groot, E., Kastelein, J. J. P., & Stroes, E. S. G.
Affiliations: Amsterdam UMC Location University of Amsterdam (NL)
ORCID: Fouchier, Sigrid W.
Hutten, Barbara A.
de Groot, Eric
Kastelein, John J.P.
Stroes, Erik S.G.
Venue: Arteriosclerosis, Thrombosis, and Vascular Biology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2005-09
Volume: 25
Issue: 9
Pages: 1979-1984
ISSN: 1079-5642 (ISSN-L)
1524-4636
DOI: 10.1161/01.atv.0000176191.64314.07
OpenAlex: W2110975556
Cited by: 106
References: 56
Citations by year: 2026: 3 · 2025: 1 · 2024: 5 · 2023: 2 · 2022: 4 · 2021: 6 · 2020: 2 · 2019: 4 · 2018: 1 · 2017: 2 · 2016: 4 · 2015: 8 · 2014: 8 · 2013: 13 · 2012: 8
FWCI: 3.86
Type: journal article
Language: en
Open access: closed
Locations: Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords: familial hypobetalipoproteinemia, hepatic steatosis, cardiovascular risk, carotid intima-media thickness, arterial stiffness, LDL cholesterol, apolipoprotein B, transaminases, cardioprotection
MeSH terms: Adult, Apolipoproteins B, Carotid Artery Diseases, Fatty Liver, Female, Humans, Hypobetalipoproteinemias, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Severity of Illness Index, Ultrasonography, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hepatic and Cardiovascular Consequences of Familial Hypobetalipoproteinemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks